JP2016517884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016517884A5 JP2016517884A5 JP2016511726A JP2016511726A JP2016517884A5 JP 2016517884 A5 JP2016517884 A5 JP 2016517884A5 JP 2016511726 A JP2016511726 A JP 2016511726A JP 2016511726 A JP2016511726 A JP 2016511726A JP 2016517884 A5 JP2016517884 A5 JP 2016517884A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- condition
- composition according
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 24
- 208000016192 Demyelinating disease Diseases 0.000 claims description 13
- 230000023105 myelination Effects 0.000 claims description 13
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 12
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 12
- 201000006417 multiple sclerosis Diseases 0.000 claims description 12
- 206010012305 Demyelination Diseases 0.000 claims description 11
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 8
- 102000006386 Myelin Proteins Human genes 0.000 claims description 8
- 108010083674 Myelin Proteins Proteins 0.000 claims description 8
- 210000005012 myelin Anatomy 0.000 claims description 8
- 210000002569 neuron Anatomy 0.000 claims description 8
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 6
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 6
- 201000001119 neuropathy Diseases 0.000 claims description 6
- 230000007823 neuropathy Effects 0.000 claims description 6
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 6
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 4
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 4
- 208000005587 Refsum Disease Diseases 0.000 claims description 4
- 208000030597 adult Refsum disease Diseases 0.000 claims description 4
- 206010008129 cerebral palsy Diseases 0.000 claims description 4
- 230000003210 demyelinating effect Effects 0.000 claims description 4
- 206010061811 demyelinating polyneuropathy Diseases 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 210000004885 white matter Anatomy 0.000 claims description 4
- 210000004404 adrenal cortex Anatomy 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000011403 Alexander disease Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 206010003694 Atrophy Diseases 0.000 claims description 2
- 208000022526 Canavan disease Diseases 0.000 claims description 2
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 claims description 2
- 206010009346 Clonus Diseases 0.000 claims description 2
- 206010010252 Concentric sclerosis Diseases 0.000 claims description 2
- 208000019505 Deglutition disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 claims description 2
- 206010021143 Hypoxia Diseases 0.000 claims description 2
- 208000008498 Infantile Refsum disease Diseases 0.000 claims description 2
- 206010022840 Intraventricular haemorrhage Diseases 0.000 claims description 2
- 208000028226 Krabbe disease Diseases 0.000 claims description 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 claims description 2
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 2
- 206010050081 Neonatal hypoxia Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 206010033885 Paraparesis Diseases 0.000 claims description 2
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims description 2
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 claims description 2
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 206010040021 Sensory abnormalities Diseases 0.000 claims description 2
- 206010044696 Tropical spastic paresis Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 206010063661 Vascular encephalopathy Diseases 0.000 claims description 2
- 206010048214 Xanthoma Diseases 0.000 claims description 2
- 201000004525 Zellweger Syndrome Diseases 0.000 claims description 2
- 208000036813 Zellweger spectrum disease Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 230000037444 atrophy Effects 0.000 claims description 2
- 206010003882 axonal neuropathy Diseases 0.000 claims description 2
- 230000033228 biological regulation Effects 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000002008 hemorrhagic effect Effects 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 230000001146 hypoxic effect Effects 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007917 intracranial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000036546 leukodystrophy Diseases 0.000 claims description 2
- 210000002332 leydig cell Anatomy 0.000 claims description 2
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 2
- 210000001428 peripheral nervous system Anatomy 0.000 claims description 2
- 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 claims description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000004193 respiratory failure Diseases 0.000 claims description 2
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 2
- 210000005070 sphincter Anatomy 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 208000009174 transverse myelitis Diseases 0.000 claims description 2
- 208000006961 tropical spastic paraparesis Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 46
- 210000003007 myelin sheath Anatomy 0.000 claims 3
- 208000030137 articulation disease Diseases 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 35
- 230000001537 neural effect Effects 0.000 description 4
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000017515 adrenocortical insufficiency Diseases 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| US61/819,467 | 2013-05-03 | ||
| USPCT/US2013/0053640 | 2013-08-05 | ||
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018118891A Division JP2018141024A (ja) | 2013-05-03 | 2018-06-22 | 髄鞘形成疾患の処置におけるソベチロム |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2016517884A JP2016517884A (ja) | 2016-06-20 |
| JP2016517884A5 true JP2016517884A5 (enExample) | 2017-03-09 |
| JP6360552B2 JP6360552B2 (ja) | 2018-07-18 |
| JP6360552B6 JP6360552B6 (ja) | 2018-08-15 |
Family
ID=51843844
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511718A Withdrawn JP2016517883A (ja) | 2013-05-03 | 2013-08-05 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| JP2016511726A Active JP6360552B6 (ja) | 2013-05-03 | 2014-02-05 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018118891A Pending JP2018141024A (ja) | 2013-05-03 | 2018-06-22 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018137754A Pending JP2018162321A (ja) | 2013-05-03 | 2018-07-23 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016511718A Withdrawn JP2016517883A (ja) | 2013-05-03 | 2013-08-05 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018118891A Pending JP2018141024A (ja) | 2013-05-03 | 2018-06-22 | 髄鞘形成疾患の処置におけるソベチロム |
| JP2018137754A Pending JP2018162321A (ja) | 2013-05-03 | 2018-07-23 | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (enExample) |
| EP (1) | EP2991670B8 (enExample) |
| JP (4) | JP2016517883A (enExample) |
| CN (1) | CN105431163A (enExample) |
| AU (1) | AU2014260468A1 (enExample) |
| BR (1) | BR112015027682A2 (enExample) |
| CA (1) | CA2911309A1 (enExample) |
| ES (1) | ES2745532T3 (enExample) |
| MX (2) | MX379043B (enExample) |
| RU (1) | RU2015151216A (enExample) |
| SG (2) | SG11201509012QA (enExample) |
| WO (2) | WO2014178892A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016517883A (ja) * | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
| JP6302091B2 (ja) | 2014-04-30 | 2018-03-28 | ザ・ジョンズ・ホプキンス・ユニバーシティー | デンドリマー組成物および眼の疾患の処置におけるその使用 |
| JP6342575B2 (ja) | 2014-08-13 | 2018-06-13 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 脳腫瘍への選択的デンドリマー送達 |
| WO2017075580A1 (en) * | 2015-10-29 | 2017-05-04 | The Johns Hopkins University | Compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
| KR102407053B1 (ko) * | 2016-04-22 | 2022-06-10 | 바이킹 테라퓨틱스 인코포레이티드 | 갑상선 베타-작용제의 사용 |
| ES2992773T3 (en) | 2016-04-22 | 2024-12-18 | Viking Therapeutics Inc | Use of thyroid beta-agonists |
| KR102331596B1 (ko) * | 2016-05-18 | 2021-11-25 | 오레곤 헬스 앤드 사이언스 유니버시티 | 소베티롬의 유도체 |
| US11325886B2 (en) | 2016-08-12 | 2022-05-10 | Oregon Health & Science University | Amide compounds, pharmaceutical compositions thereof, and methods of using the same |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| EP3615086A4 (en) | 2017-04-27 | 2021-01-06 | The Johns Hopkins University | COMPOSITIONS OF DENDRIMERS FOR USE IN ANGIOGRAPHY |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| US11660281B2 (en) | 2017-06-29 | 2023-05-30 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| JP7109794B2 (ja) | 2017-07-18 | 2022-08-02 | 慶應義塾 | Ｔｈ１細胞誘導性細菌に対する抗菌組成物 |
| CN111615528A (zh) | 2017-11-10 | 2020-09-01 | 约翰霍普金斯大学 | 树枝状聚合物递送系统和其使用方法 |
| CA3122996A1 (en) | 2018-12-12 | 2020-06-18 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| EP3931180A1 (en) | 2019-03-01 | 2022-01-05 | Autobahn Therapeutics, Inc. | Novel thyromimetics |
| KR20220121239A (ko) | 2019-11-29 | 2022-08-31 | 아우토반 쎄라퓨틱스, 인크. | 신규한 갑상선 호르몬 모방제 |
| JP7759322B2 (ja) | 2019-12-04 | 2025-10-23 | アシュバッタ セラピューティクス， インコーポレイテッド | 眼に薬物送達するためのデンドリマー組成物および方法 |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| EP0873361B1 (en) | 1995-12-13 | 2006-11-02 | The Regents Of The University Of California | Crystals of the ligand-binding domain of the thyroid hormone receptor complexed to a ligand |
| US6054485A (en) | 1996-08-20 | 2000-04-25 | Regents Of The University Of California | Eye treatments using synthetic thyroid hormone compositions |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| EP1598334A1 (en) | 1998-06-30 | 2005-11-23 | The Regents Of The University Of California | Thyroid hormone analogues and methods for their preparation |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| EP2335694B1 (en) * | 2003-09-15 | 2018-06-13 | NanoPharmaceuticals LLC | Thyroid hormone analogs and methods of use |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| CN101102758B (zh) | 2004-09-15 | 2011-11-16 | 奥德威研究院 | 促进血管新生的甲状腺激素类似物 |
| US20090117054A1 (en) | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| WO2008049053A2 (en) * | 2006-10-20 | 2008-04-24 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| CA2704279C (en) * | 2006-11-03 | 2014-09-30 | University Of Saskatchewan | Method of treating demyelination diseases |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| CA2970273C (en) * | 2007-07-11 | 2020-04-14 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| WO2009097995A1 (de) * | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2278999B1 (en) | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| MX2011012078A (es) | 2009-05-20 | 2012-03-14 | Lingual Consegna Pty Ltd | Formulacion terapeutica bucal y/o sublingual. |
| TW201221505A (en) * | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| EA031156B1 (ru) | 2010-12-16 | 2018-11-30 | Суновион Фармасьютикалз Инк. | Сублингвальные пленки |
| EP2911924B1 (en) * | 2012-10-25 | 2017-06-21 | Volvo Truck Corporation | Electronically controlled pneumatic brake system for an automotive vehicle, automotive vehicle equipped with such a system and method for controlling such a system |
| JP2016517883A (ja) | 2013-05-03 | 2016-06-20 | オレゴン ヘルス アンド サイエンス ユニバーシティー | Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用 |
-
2013
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en not_active Ceased
-
2014
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en not_active Ceased
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016517884A5 (enExample) | ||
| RU2015151216A (ru) | Собетиром для лечения заболеваний, связанных с миелинизацией | |
| Crespel et al. | Management of juvenile myoclonic epilepsy | |
| Hagerman et al. | The fragile X family of disorders: a model for autism and targeted treatments | |
| Magana et al. | Spinocerebellar ataxia type 2: clinical presentation, molecular mechanisms, and therapeutic perspectives | |
| Qiu et al. | Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica | |
| Xu et al. | Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study | |
| JP2021080269A5 (enExample) | ||
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| JP2018531965A5 (enExample) | ||
| Wang et al. | Adolescent microglia stimulation produces long-lasting protection against chronic stress-induced behavioral abnormalities in adult male mice | |
| Alme et al. | Fingolimod does not enhance cerebellar remyelination in the cuprizone model | |
| CA2986891C (en) | Compositions for use in treating parkinson's disease and related disorders | |
| Tan et al. | Pharmacological therapies for Angelman syndrome | |
| Sienaert et al. | Adult catatonia: etiopathogenesis, diagnosis and treatment | |
| Juhi et al. | Ataxia, manifestation of phenytoin toxicity: A case report | |
| Duggal | Ziprasidone for maladaptive behavior and attention-deficit/hyperactivity disorder symptoms in autistic disorder | |
| Arhan et al. | Drug treatment failures and effectivity in children with newly diagnosed epilepsy | |
| US20090099259A1 (en) | Method for regulating gene expression | |
| Ozen et al. | Topiramate add-on for treatment of migraine-type headache cures alcohol dependence: A case report | |
| Gautier et al. | Maternal choline supplementation rescues early endosome pathology in basal forebrain cholinergic neurons in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease | |
| Anstey | Fumaric acid esters in the treatment of psoriasis–commentary on ‘Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study’by Wain et al. | |
| Sookaromdee et al. | Adverse Effects of Telemedicine | |
| JP2018500375A5 (enExample) | ||
| Banerji et al. | Treatment with field bean protease inhibitor can effectively repress ethylnitrosourea (ENU)-induced neoplasms of the nervous system in Sprague–Dawley rats |